skin substitute companies, their product development activities, and strategies
reports the fully functional regeneration of a salivary gland that reproduces the morphogenesis induced by reciprocal epithelial and mesenchymal interactions through the orthotopic transplantation of a bioengineered
salivary gland germ as a regenerative organ replacement therapy.
FDA has no basis for concluding that bioengineered
foods differ from other foods in any meaningful or uniform way, or that, as a class, foods developed by the new techniques present any different or greater safety concern than foods developed by traditional plant breeding," says Richard Herndon, an FDA spokesperson.
To date, biotechnology firms have completed consultation with FDA on more than 40 food products, and a substantial portion of American cropland is planted with bioengineered
Nonetheless, regulators have focused less on the safety of bioengineered
foods than on the techniques behind them.
Previous studies have examined how the drift of Bt pollen affects monarch butterflies or wild plants related to the bioengineered
crops (SN: 9/15/01, p.
Rivkah Isseroff, MD, professor of dermatology at UC Davis and director of a laboratory that produces bioengineered
skin replacements, and Ivan Schwab, MD, professor of ophthalmology, spent 10 years perfecting their procedure, which they described in the July issue of the journal Cornea.
a medical device company based in Rockland, Massachusetts, seeks to pioneer and commercialize minimally invasive diagnostic and therapeutic applications based on proprietary bioengineered
Use this report to: - Receive information about the current and future global market for bioengineered
The Humacyte investigational bioengineered
blood vessel technology represents a research and development milestone in vascular tissue engineering.
Preclinical data on Humacyte's proprietary bioengineered
blood vessel technology was reported today at an American Heart Association Emerging Science Series webinar
NASDAQ: BSMD), a medical device company that pioneered the use of bioengineered
microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a procedure called embolization, announced today that Richard Faleschini, President and Chief Executive Officer, is scheduled to present at Rodman & Renshaw's 8th Annual Healthcare Conference on Monday, November 6, 2006 at 12:25 PM Eastern Time.